2017 American Transplant Congress
Even Non-Donor-Specific HLA-Antibodies Are Associated with a Progressive Decline in Kidney Transplant Function.
University Spital Zuerich, Zuerich, Switzerland
Donor-specific anti-HLA-Antibodies (DSA) have been shown to be associated with antibody-mediated rejection episodes and a poorer long-term kidney graft function. The impact of anti-HLA-antibodies without…2017 American Transplant Congress
Kidney Waitlist Management: The Readiness Model of Predicting Transplants Under the Kidney Allocation System.
Transplant Center, Massachusetts General Hospital, Boston, MA
Based on the Organ Procurement and Transplantation Network data, between 2001 and 2016 the national kidney wait-list has grown from 51,271 to 100,791 (97%). At…2017 American Transplant Congress
It's Never too Early to Test: Frequent Anti-A2 Titer Monitoring in Blood Group B Patients is Necessary.
Medstar Georgetown Transplant Institute, Washington, DC
Introduction:With the implementation of the new Kidney Allocation System (KAS), deceased donor transplants from blood group A2 donors can now be implanted into blood group…2017 American Transplant Congress
Tacrolimus Appears to Be a Protective Factor for De Novo DSA Formation in Non-Sensitized Kidney Transplant Patients.
Background.Development of de novo donor specific antibodies (dnDSA) concerns about 10% of patients within the first year following kidney transplantation and reach about 20% within…2017 American Transplant Congress
Contribution of New Generation Sequencing to CMV Resistance Analysis in Renal Transplant Recipients (on Behalf of the CMV Resist Group).
Results from the French Cohorts 2006-2010 and OrphaVic (NCTNCT02067169) indicates that fifty percent of graft failures in renal recipients infected by HCMV after treatment with…2017 American Transplant Congress
mTOR Inhibition Diminishes Peripheral Blood CD8+CD28–CD38hi Effector/Memory T Cells and Facilitates Resolution of Belatacept-Refractory Kidney Rejection.
Belatacept, a CD28-CD80/86 blocker, was approved by the FDA to provide immunosuppression without nephrotoxicity or cardiovascular and metabolic adverse effects. As part of our multi-center…2017 American Transplant Congress
Advanced Donation within a Paired Exchange Program.
BACKGROUND:Advanced Donation (ADP) within Kidney Paired Donation (KDP) occurs when a donor is time-limited and chooses to donate a kidney before their intended recipient with…2017 American Transplant Congress
Tacrolimus Time in Therapeutic Range Predicts Adverse Clinical Outcomes in the First Year of Kidney Transplant.
University of Colorado, Aurora, CO
Tacrolimus (TAC) has a narrow therapeutic range, with its upper bounds limited by serious toxicities while TAC minimization strategies have demonstrated immunologic risk. Monitoring the…2017 American Transplant Congress
A Possible Unintended Consequence of the Kidney Allocation System: The Effect of Duration of Dialysis on Mental Health Outcomes.
Purpose: Long-term dialysis has been shown to adversely affect physical health-related quality of life (HRQOL) but its effect on mental HRQOL and symptoms of depression…2017 American Transplant Congress
Induction of Proliferative Responses in B Cell and Plasma Cell Populations Following Proteasome Inhibitor Desensitization Treatment in Rhesus Macacques and Humans.
1U of Cincinnati, Cincinnati; 2Duke, Durham; 3Cincinnati Childrens, Cincinnati
Proteasome inhibitor (PI)-based desensitization (DS) in humans has demonstrated variable reduction in HLA antibody levels that is often associated with variable rebound following treatment cessation.The…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 181
- Next Page »